InspireMD Inc. · NASDAQ:NSPR
InspireMD — Investor Presentation (January 2021)
25 slides from InspireMD's investor presentation, Jan 15, 2021
Slide 1: Sustained Embolic Protection
Sustained Embolic Protection Jan. 15, 2021 http://www.inspiremd.com/en/ 1
Slide 2: Disclaimers
Disclaimers This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements ar
Slide 3: About InspireMD
About InspireMD InspireMD is a commercial-stage medical device company focused on stroke prevention in patients with carotid artery disease and treatment of other minimally MicroNet™ is a proprietary platform invasive indications utilizing an comprised of thin, 20-micron polyethylene terephthalate m
Slide 4: Our Leadership
Our Leadership Mr. Slosman has over 30 years of experience in the medical device industry with focused Marvin L. Slosman leadership in commercialization and international market development President and CEO in both public and privately held companies. He has had senior management roles in a variety
Slide 5: InspireMD Pipeline
InspireMD Pipeline Commercial Stage The CGuardTM Carotid Stent with Embolic Prevention System Stroke Protection: (EPS) is designed to improve patient safety through sustained CGuardTM EPS embolic protection1,2 using our MicroNet™ technology. Myocardium Protection: The MGuard EPS, integrated with Mic
Slide 6: Endovascular Procedures: Landscape and InspireMD Potential
E n d o v a s c u l a r P r o c e d u r e s : L a n d s c a p e a n d I n s p i r e M D Po t e n t i a l CAD market CEREBRAL CORONARY THORACIC/ PERIPHERAL CAROTID potential ANEURYSMS ARTERY DISEASE ABDOMINAL AORTIC ARTERIAL DISEASE ARTERY open to ANEURYSMS (PAD) DISEASE endo conversion 70% Endo1 77%
Slide 7: Stroke is the Second Biggest Cause of Death Globally
St r o k e i s t h e S e c o n d B i g g e s t C a u s e o f D e a t h G l o b a l l y An estimated 15 million people suffer from stroke annually1 • 6.2 million deaths2 Top Two Causes of Death Globally (2016)6 • 5 million people left permanently disabled1 10 9 • $34 billion associated with stroke ma
Slide 8: THE PROBLEM: Risks with Existing Approaches to CAD
THE PROBLEM: Risks with Existing Approaches to CAD Surgery (CEA) and conventional Carotid Artery Stenting (CAS) both come with risks Carotid Endarterectomy (CEA) Carotid Artery Stenting (CAS) Surgical Approach Conventional Approach (Bare Stent) Risk of complications: Risk of complications: • Myocard
Slide 9: THE PROBLEM: Risk of Embolism Following Conventional CAS
THE PROBLEM: Risk of Embolism Following Conventional CAS MRI reveals post-procedural cerebral embolization Pre-Procedure Post-Procedure with Conventional Stent 90% occlusion MRI of a pre-existing white Successful MRI reveals new multiple micro- of the carotid matter infarction opening of the infarct
Slide 10: OUR SOLUTION: Proprietary MicroNet Technology
O U R S O L U T I O N : P r o p r i e t a r y M i c r o N e t T M Te c h n o l o g y New mesh covered stent that offers superior plaque coverage when compared to conventional stent approaches MicroNetTM: an Embolic Prevention System (EPS) for Ultimate Thrombus Protection • Ultrathin flexible mesh sl
Slide 11: Mechanics Translate to Clinical Results
M e c h a n i c s Tr a n s l a t e t o C l i n i c a l Re s u l t s CGUARD™ *165µ 1050µ 1900µ 375µ 500µ Closed cell stent Open cell stent TERUMO GORE * Average in lesion at expanded state Musialek, Piotr, MD DPHIL. Mesh-Covered Stents for Carotid Intervention: Rationale, Device Designs, Imaging and
Slide 12: CGuard Shows Superiority Over Terumo RoadSaver at 1 yr
CG u a r d ™ S h o w s S u p e r i o r i t y O v e r Te r u m o Ro a d S a v e r a t 1 y r META-ANALYSIS PUBLICATION UPDATE: Patient-level meta-analysis, 556 patients / 4 trials (both symptomatic and asymptomatic) ✅ CGuard on track, demonstrating SUPERIORITY DUAL LAYER STENT 1 YEAR DATA (cumulative
Slide 13: Carotid Solution: Our Well Studied Mesh-Covered Technology
C a r o t i d S o l u t i o n : O u r We l l St u d i e d M e s h - C o v e r e d Te c h n o l o g y More than 1,500 patients in Clinical Publications and Studies 13
Slide 14: Timeline Growth: From Alternative Stent to New Gold Standard
Timeline Growth: From Alternative Stent to New Gold Standard YEAR STUDY PUBLICATION HIGHLIGHTS CGUARD’S STANDING (known & anticipated) 2015 CARENET Safety, Efficacy & Neuroprotection over other stents data 2016 PARADIGM All comers population; Excellent clinical results CGuard evaluated as new appr
Slide 15: CGuard EPS Yields Superior Clinical Outcomes
CG u a r d ™ E P S Y i e l d s S u p e r i o r C l i n i c a l O u t c o m e s When compared with Conventional Stents and Surgery (CEA), CGuardTM trends Superior 30 Day DSM (Death, Stroke, Myocardial Infarction) • CGuard™ has a superior profile versus 6.00% historical data on both conventional 5.20%
Slide 16: A Billion Dollar Market Opportunity
A Billion Dollar Market Oppor tunity Our MicroNetTM-covered stents like CGuardTM could become the new gold standard WW carotid procedures today are Carotid procedures tomorrow could be primarily surgical: mostly minimally invasive with CGuard™ • 2.2M diagnosed (and potentially as many as 13 million
Slide 17: Commercial Footprint
Commercial Footprint (Dark Blue) • Active Selling in 33 Countries • Over 90% of sales are through channel partners / distributors • Short Term Expansion Brazil and France • New countries development include Japan, S Korea and China • IDE approval in September 2020; targeting initiation of US trial i
Slide 18: Growth Pathway to the U.S. Market
Growth Pathway to the U.S. Market U.S. Market Opportunity* Size: 192K High Grade Carotid Artery Stenosis (HGCS) interventions in 2017 Opportunity : At a price of $1,650 per stent, the addressable market is estimated to be approximately $317 million Executing on Approval of FDA PMA for U.S. M
Slide 19: Our Lead Product, CGuard - Advancing Rapidly
O u r L e a d P r o d u c t , CG u a r d T M - A d v a n c i n g R a p i d l y CGuardTM has potential 31% 20,000+ Pre- and Post-Procedure with CGuardTM to become the new standard-of-care for carotid indications Total protected growth of *Achieved clinical stents sold to date CGuardTM milestones; wit
Slide 20: Our Advancement Roadmap / Milestones
O u r A d v a n c e m e n t Ro a d m a p / M i l e s t o n e s Key Value Drivers and Strategic Pathways 2020 2021 2022 and Commercial Focus Beyond Market Awareness / Data Transform CAS Globally Expand Broad Global Capability, Share & Commercial Growth Growth Embolic Protection Invest in Platform Ind
Slide 21: Our Robust Intellectual Property Portfolio
O u r Ro b u s t I n t e l l e c t u a l P r o p e r t y Po r t f o l i o Proprietary platform technology supported by IP Patent Rights Issued Allowed Pending • InspireMD will continue to USA 14 1 3 strengthen and broaden its patent protection globally to enable future pipeline products Rest of Worl
Slide 22: Our Business and Market Development
Our Business and Market Development Strategic Targets for Merger or Acquisition Synergy Size 22
Slide 23: The carotid space is seeing investment
The carotid space is seeing investment Annual Revenue ($MM) $80.0 October First commercial case $70.0 $72.1 2015 $60.0 $63.3 $50.0 April IPO; $600 million valuation $40.0 2019 $34.6 $30.0 $2 billion current valuation $20.0 $14.3 January $10.0 2021 $- 2017 2018 2019 2020* * Annualized from Q1-Q3 actu
Slide 24: Summary Financials
Summar y Financials NYSE AMERICAN NSPR Stock Price (1/13/21): $0.66 Average volume: 5.1 M Shares outstanding (1/13/21): 61.7 M Shares outstanding including full conversion of 64.8 M preferred shares (1/12/21): Market capitalization including full conversion of $42.8 M preferred shares (1/12/21): Cas
Slide 25: Thank you
Thank you http://www.inspiremd.com/en/ 25